Amgen AMGN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Amgen (AMGN) Business Model and Operations Summary
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Key Insights
Amgen (AMGN) Core Market Data and Business Metrics
Latest Closing Price
$306.92Market Cap
$164.15 BillionPrice-Earnings Ratio
39.25Total Outstanding Shares
536.44 Million SharesTotal Employees
26,700Dividend
$2.38 Per Share QuarterlyIPO Date
June 17, 1983SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
One Amgen Center Drive, Thousand Oaks, CA, 91320
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $7.26 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-5.25 Billion |
| Net Cash Flow From Financing Activities | $-5.25 Billion |
| Net Cash Flow | $-25.73 Billion |
| Net Cash Flow From Operating Activities, Continuing | $7.26 Billion |
| Net Cash Flow, Continuing | $-25.73 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $4.23 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income/Loss From Equity Method Investments | $-17 Million |
| Net Income/Loss Attributable To Parent | $4.23 Billion |
| Gross Profit | $19.68 Billion |
| Income/Loss From Continuing Operations Before Tax | $4.68 Billion |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $-210 Million |
| Comprehensive Income/Loss | $3.89 Billion |
| Other Comprehensive Income/Loss | $-2.70 Billion |
| Comprehensive Income/Loss Attributable To Parent | $4.02 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Long-term Debt | $60.40 Billion |
| Intangible Assets | $28.92 Billion |
| Other Current Assets | $19.40 Billion |
| Current Assets | $26.77 Billion |
| Equity | $7.53 Billion |
| Noncurrent Liabilities | $63.04 Billion |
Historical Dividends
Current dividend: $2.38 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Mar 4, 2025 | Jun 6, 2025 | May 16, 2025 | $2.38 | Quarterly |
| Dec 10, 2024 | Mar 7, 2025 | Feb 14, 2025 | $2.38 | Quarterly |
| Oct 25, 2024 | Dec 9, 2024 | Nov 18, 2024 | $2.25 | Quarterly |
| Aug 2, 2024 | Sep 6, 2024 | Aug 16, 2024 | $2.25 | Quarterly |
| Mar 6, 2024 | Jun 7, 2024 | May 17, 2024 | $2.25 | Quarterly |
| Dec 12, 2023 | Mar 7, 2024 | Feb 16, 2024 | $2.25 | Quarterly |